Evidence map›Paper›PMID 28830573›Full record

ArticleBreast cancer research : BCR2017

Assessment of the prognostic role of a 94-single nucleotide polymorphisms risk score in early breast cancer in the SIGNAL/PHARE prospective cohort: no correlation with clinico-pathological characteristics and outcomes.

Elsa Curtit, Xavier Pivot, Julie Henriques, Sophie Paget-Bailly, Pierre Fumoleau, Maria Rios, Hervé Bonnefoi, Thomas Bachelot, Patrick Soulié, Christelle Jouannaud and 28 more

Registry-linked trialOpen access · goldAbstract read
In one paragraph

Article in Breast cancer research : BCR, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT00381901 (Protocol of Herceptin Adjuvant With Reduced Exposure, a Randomised Comparison of 6 Months vs 12 Months in All Women Receiving Adjuvant Herceptin [PHARE]), which is not on this map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
1.5field-weighted citation impact, top 15% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT00381901 phase3completednot on this map

Protocol of Herceptin Adjuvant With Reduced Exposure, a Randomised Comparison of 6 Months vs 12 Months in All Women Receiving Adjuvant Herceptin [PHARE]

TypeinterventionalSponsorNational Cancer Institute, FranceRan2006Enrolled3,400ConditionsBreast CancerArmstrastuzumab, polymorphism analysis, adjuvant therapy
3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 9 citations in OpenAlex.

  1. Associations of a Breast Cancer Polygenic Risk Score With Tumor Characteristics and Survival.Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 2023
    Article
  2. Article
  3. Review
  4. Article
  5. Article
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

38 authors at 20 institutions in 1 country.

Elsa CurtitHôpital Jean-Minjoz, Centre Hospitalier Universitaire, UMR 1098 INSERM-EFS-Université de Bourgogne Franche-Comté, Boulevard Fleming, 25000, Besançon, France. elsa.curtit@univ-fcomte.fr.
Xavier PivotHôpital Jean-Minjoz, Centre Hospitalier Universitaire, UMR 1098 INSERM-EFS-Université de Bourgogne Franche-Comté, Boulevard Fleming, 25000, Besançon, France.
Julie HenriquesCentre Hospitalier Universitaire, Unité de Méthodologie et de Qualité de Vie en Cancérologie, 2 place St Jacques, 25000, Besançon, France.
Sophie Paget-BaillyCentre Hospitalier Universitaire, Unité de Méthodologie et de Qualité de Vie en Cancérologie, 2 place St Jacques, 25000, Besançon, France.
Pierre FumoleauGeorges-François Leclerc, 1 Rue du Professeur Marion, 21000, Dijon, France.
Maria RiosInstitut de Cancérologie de Lorraine - Alexis Vautrin, département d'Oncologie Médicale, 6, avenue de Bourgogne, 54511, Vandoeuvre Les Nancy Cedex, France.
Hervé BonnefoiInstitut Bergonié, Département d'Oncologie Médicale, 229 Cours de l'Argonne, 33000, Bordeaux, France.
Thomas BachelotCentre Léon Bérard, Département de Cancérologie Médicale, 28 rue Laënnec, Lyon Cedex 08, France.
Patrick SouliéInstitut de Cancérologie de l'Ouest, Service Oncologie Médicale, 2 rue Moll, 49993, Angers Cedex 09, France.
Christelle JouannaudInstitut Jean Godinot, Service Oncologie Médicale, 1 rue du Général Koenig, 51056, Reims cedex, France.
Hugues BourgeoisClinique Victor Hugo-Centre Jean Bernard, 18 rue Victor Hugo, 72015, Le Mans Cedex 2, France.
Thierry PetitCentre Paul Strauss, Service d'Oncologie Médicale, 3 rue de la Porte de l'Hôpital, 67065, Strasbourg Cedex, France.
Isabelle TennevetCentre Henri Becquerel, rue d'Amiens, 76038, Rouen, France.
David AssoulineInstitut Daniel Hollard, Service Oncologie Médicale, 8 rue du Docteur Calmette, 38028, Grenoble Cedex 01, France.
Marie-Christine MathieuInstitut Gustave Roussy, Comité de Pathologie mammaire, 39 rue Camille Desmoulins, 94805, Villejuif Cedex, France.
Jean-Philippe JacquinInstitut de Cancérologie Lucien Neuwirth, Service Oncologie Médicale, 108 bis avenue Albert Raimond, 42270, Saint Priest en Jarez, France.
Sandrine Lavau-DenesCentre Hospitalier de Limoges, Service d'Oncologie Médicale, 2 avenue Martin Luther King, 87042, Limoges Cedex, France.
Ariane Darut-JouveClinique Drévon, Centre d'oncologie et de radiothérapie du Parc, 18 cours du général de Gaulle, 21000, Dijon, France.
Jean-Marc FerreroCentre Antoine Lacassagne, Département Oncologie Médicale, 33 avenue de Valombrose, 06189, Nice Cedex 02, France.
Carole TarpinInstitut Paoli-Calmettes, Département d'Oncologie Médicale, 232 Boulevard de Sainte-Marguerite, 13009, Marseille, France.
Christelle LévyCentre François Baclesse, 3 avenue du Général Harris, 14076, Caen Cedex 5, France.
Valérie DelecroixCentre Etienne Dolet, Pôle Mutualiste, Service Oncologie Médicale, 11 boulevard Georges Charpak, 44606, Saint Nazaire, France.
Véronique Trillet-LenoirCentre Hospitalier Lyon Sud, Service d'Oncologie Médicale, 165 chemin du Grand Revoyet, 69495, Pierre-Benite Cedex, France.
Oana CojocarasuCentre Hospitalier Le Mans, Service d'Onco-Hématologie et Médecine interne, 194 avenue Rubillard, 72037, Le Mans Cedex, France.
Jérôme MeunierCentre Hospitalier Régional d'Orléans, Service d'Oncologie médicale, 1 rue Porte Madeleine, 45032, Orleans Cedex 1, France.
Jean-Yves PiergaInstitut Curie, Department of Medical Oncology, 26 rue d'Ulm, 75248, Paris Cedex 05, France.
Pierre KerbratCentre Eugène Marquis, Service Oncologie médicale, Rue de la Bataille Flandres-Dunkerque, CS 44229, 35042, Rennes Cedex, France.
Céline Faure-MercierInstitut National du Cancer, Direction de la Recherche, 52 avenue Morizet, 92513, Boulogne-Billancourt, France.
Hélène BlanchéCentre d'Etudes du Polymorphisme Humain, 27 rue Juliette Dodu, 75010, Paris, France.
Mourad SahbatouCentre d'Etudes du Polymorphisme Humain, 27 rue Juliette Dodu, 75010, Paris, France.
Anne BolandCentre National du Génotypage, 2 rue Gaston Crémieux, CP 5721, 91057, Evry Cedex, France.
Delphine BacqCentre National du Génotypage, 2 rue Gaston Crémieux, CP 5721, 91057, Evry Cedex, France.
Céline BesseCentre National du Génotypage, 2 rue Gaston Crémieux, CP 5721, 91057, Evry Cedex, France.
Gilles ThomasSynergie Lyon Cancer, Centre Léon Bérard, 28 rue Laënnec, Lyon Cedex 08, France.
Jean-François DeleuzeCentre d'Etudes du Polymorphisme Humain, 27 rue Juliette Dodu, 75010, Paris, France.
Iris PauportéInstitut National du Cancer, Direction de la Recherche, 52 avenue Morizet, 92513, Boulogne-Billancourt, France.
Gilles RomieuOncologie Sénologie, ICM Institut Régional du Cancer, 34298, Montpellier Cedex, France.
David G CoxCentre de Recherche en Cancérologie de Lyon, INSERM U1052 - Centre Léon Bérard, 28 rue Laennec, 69373, Lyon, France.
Centre National de Recherche en Génomique Humaine · FRFondation Jean Dausset-CEPH · FRInserm · FRCentre Léon Bérard · FRInstitut National du Cancer · FRMethodology and Quality of Life Unit in Oncology · FRCentre Antoine Lacassagne · FRCentre Eugène Marquis · FRCentre François Baclesse · FRCentre Georges François Leclerc · FRCentre Hospitalier du Mans · FRCentre Hospitalier Universitaire de Limoges · FRCentre hospitalier universitaire d'Orléans · FRCentre Jean Bernard · FRClinique Mutualiste de l'Estuaire · FRGroupe d'Oncologie Radiothérapie Tête et Cou · FRHôpital Civil, Strasbourg · FRHôpital Lyon Sud · FRInstitut Bergonié · FRInstitut Curie · FR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundGenome-wide association studies (GWAS) have to date identified 94 genetic variants (single nucleotide polymorphisms (SNPs)) associated with risk of developing breast cancer. A score based on the combined effect of the 94 risk alleles can be calculated to measure the global risk of breast cancer. We aimed to test the hypothesis that the 94-SNP-based risk score is associated with clinico-pathological characteristics, breast cancer subtypes and outcomes in early breast cancer.

methodsA 94-SNP risk score was calculated in 8703 patients in the PHARE and SIGNAL prospective case cohorts. This score is the total number of inherited risk alleles based on 94 selected SNPs. Clinical data and outcomes were prospectively registered. Genotyping was obtained from a GWAS.

resultsThe median 94-SNP risk score in 8703 patients with early breast cancer was 77.5 (range: 58.1-97.6). The risk score was not associated with usual prognostic and predictive factors (age; tumor, node, metastasis (TNM) status; Scarff-Bloom-Richardson grade; inflammatory features; estrogen receptor status; progesterone receptor status; human epidermal growth factor receptor 2 (HER2) status) and did not correlate with breast cancer subtypes. The 94-SNP risk score did not predict outcomes represented by overall survival or disease-free survival.

conclusionsIn a prospective case cohort of 8703 patients, a risk score based on 94 SNPs was not associated with breast cancer characteristics, cancer subtypes, or patients' outcomes. If we hypothesize that prognosis and subtypes of breast cancer are determined by constitutional genetic factors, our results suggest that a score based on breast cancer risk-associated SNPs is not associated with prognosis.

trial registrationPHARE cohort: NCT00381901 , Sept. 26, 2006 - SIGNAL cohort: INCa RECF1098, Jan. 28, 2009.

Indexed as

Genetic Association StudiesGenetic Predisposition to DiseasePolymorphism, Single NucleotideAdultAgedAged, 80 and overAllelesBiomarkers, TumorBreast NeoplasmsClinical Trials, Phase III as TopicCohort StudiesFemaleGenotypeHumansMiddle AgedNeoplasm GradingBiomarkers, TumorBreast cancerGenetic variantPrognosisRisk scoreSingle nucleotide polymorphism

Identifiers

PMID28830573
PMCPMC5568360
OpenAlexW2750059462

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.